MD Anderson has numerous presentations throughout the 2025 ASH Annual Meeting. All times listed in Eastern Time.
MD Anderson has numerous presentations throughout the 2025 ASH Annual Meeting. All times listed in Eastern Time.
Friday, December 5
Scientific Workshops
Scientific Workshop on Aging and Hematology
3:00–6:00 p.m.
Orange County Convention Center W312
A New Horizon in Hematology: Novel Strategies for Reversing Aging
5:16–5:57 p.m.
Targeting BCL Pathways with PROTACs: A New Avenue for Modulating Aging
Speaker: Daisy Diaz-Rohena, Ph.D.
Panel discussion and cross-examination of the position; post-session polling
Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
3:00–6:00 p.m.
Orange County Convention Center W307
Disease Models and Mechanisms: Bridging the Gap
3:06–3:48 p.m.
U2AF1S34 Mutations Activate Telomerase to Overcome Telomere Dysfunctions in Patients with Telomere Biology Disorders
Speaker: Simona Colla, Ph.D.
Saturday, December 6
Oral Abstract Sessions
617. Acute Myeloid Leukemias: Commercially Available Therapies: Frontline Treatment with Intensive or Lower-Intensity Regimens
9:30–11:00 a.m.
Orange County Convention Center Valencia Room W415A
Abstract 45: Long-term follow-up of azacitidine, venetoclax and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia
Speaker: Roberta Santos Azevedo, M.D.
Abstract 47: Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML
Speaker: Wei-Ying Jen, B.M., B.Ch.
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation
9:30–11:00 a.m.
Orange County Convention Center W224ABEF
Abstract 89: Pirtobrutinib, venetoclax and obinutuzumab for patients with richter transformation: A Phase II trial
Speaker: Nitin Jain, M.D.
907. Outcomes Research: Plasma Cell Disorders: Real-world Outcomes of Targeted Immunotherapies in Patients with Multiple Myeloma
9:30–11:00 a.m.
Orange County Convention Center West Hall E2
Abstract 137: Talquetamab for relapsed/refractory multiple myeloma: Real-world outcomes from the U.S. multiple myeloma immunotherapy consortium
Speaker: Oren Pasvolsky, M.D.
624. Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling and Predictive Tools
12:00–1:30 p.m.
Orange County Convention Center Tangerine Ballroom F2
Abstract 153: Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin and dacarbazine: Phase II study
Speaker: Hun Lee, M.D.
701. Experimental Transplantation: Basic and Translational: GVHD, Thymopoiesis and the Host Regenerative Response
12:00–1:30 p.m.
Orange County Convention Center Chapin Theater (W320)
Abstract 162: Lachnospiraceae-mediated bile acid metabolism promotes ileal epithelial regeneration following graft-versus-host disease damage
Speaker: Eiko Hayase, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients
12:00–1:30 p.m.
Orange County Convention Center W331
Abstract 168: Older donor age is not associated with inferior survival in contemporary haploidentical transplantation
Speaker: Yosra Aljawai, M.D.
301. Platelets and Megakaryocytes: Basic and Translational: Novel Mechanisms of Platelet Signaling
2:00–3:30 p.m.
Orange County Convention Center W304ABCD
Abstract 196: Hypomethylation agent improves late-stage megakaryocyte maturation in MDS
Speaker: Yue Wei, Ph.D.
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Redefining AML: Genetic, Phenotypic and Response-Based Insights
2:00–3:30 p.m.
Orange County Convention Center W414AB
Abstract 222: Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia
Speaker: Yi June Kim
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes
2:00–3:30 p.m.
Orange County Convention Center Valencia Room W415BC
Abstract 235: Subgroup analyses from the randomized, Phase III VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk myelodysplastic syndromes (HR MDS)
Speaker: Guillermo Garcia-Manero, M.D.
Abstract 237: Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase I/II clinical trial
Speaker: Alex Bataller, M.D., Ph.D.
655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma
2:00–3:30 p.m.
Orange County Convention Center West Hall E1
Abstract 256: Phase II registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine-1
Speaker: Krina Patel, M.D.
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies
2:00–3:30 p.m.
Abstract 263: Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes
Presenter: Muharrem Muftuoglu, M.D.
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Beyond Genomic Resistance: Epigenetics, Metabolism and More
4:00–5:30 p.m.
Orange County Convention Center W230
Abstract 330: The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells
Speaker: Michael Wang, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients
4:00–5:30 p.m.
Orange County Convention Center Sunburst Room (W340)
Abstract 378: Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa and venetoclax (Cladillac) conditioning for high-risk AML: A Phase II trial
Speaker: Uday Popat, M.D.
802. Chemical Biology and Experimental Therapeutics: Novel Therapeutics in Hematologic Malignancies?
4:00–5:30 p.m.
Orange County Convention Center W331
Abstract 388: First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma and solid tumor models
Speaker: Jun Wei, M.D., Ph.D.
Abstract 390: First-in-class dual BTK-MALT1 fusion inhibitors for treating resistant mantle cell lymphoma
Speaker: Vivian Jiang, Ph.D.
Education Program
Complementopathies: Modern Diagnosis and Management
2:00–3:15 p.m.
Hyatt Regency Ballroom S
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS
Speaker: Vahid Afshar-Kharghan, M.D.
Blood Journals Studio
Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work
2:00–2:45 p.m.
Orange County Convention Center West Halls B3–B4
Speaker: Sanam Loghavi, M.D.
Scientific Program
Innovative Models of Lymphoma
2:00–3:15 p.m.
Orange County Convention Center West Hall E2
Utilizing refined lymphoma models for treatment studies: Innovations in syngeneic transplants, patient-derived xenografts and humanized mouse models
Speaker: Michael Green, Ph.D.
Special-Interest Sessions
Joint Session: Advancing Hematology Through Artificial Intelligence
4:00–5:30 p.m.
Hyatt Regency Ballroom S
Diagnostics & implementation: Smart diagnostics: Implementing AI in hematopathology
Speaker: Sanam Loghavi, M.D.
Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology I
6:30–8 p.m.
Hyatt Florida Ballroom A
Long-term lymphoma follow-up survey (LTL-FUS)
6:30–8:00 p.m.
Speaker: Chijioke Nze, M.D.
Sunday, December 7
Oral Abstract Sessions
621. Lymphomas: Translational – Molecular and Genetic - Decoding Lymphomagenesis through Multiomics
9:30–11:00 a.m.
Orange County Convention Center Tangerine Ballroom F1
Abstract 460: Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states
Speaker: Minghao Dang
623. Mantle Cell, Follicular, Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Immunotherapies for Follicular Lymphoma
9:30–11:00 a.m.
Orange County Convention Center West Hall D2
Abstract 467: Three-year efficacy and longitudinal safety of lisocabtagene maraleucel (liso-cel) in patients with third-line or later (3L+) follicular lymphoma (FL) from TRANSCEND FL
Speaker: Sairah Ahmed, M.D.
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas
9:30–11:00 a.m.
Orange County Convention Center Tangerine Ballroom F3-4
Abstract 477: Primary analysis of the Smart Stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma
Speaker: Jason Westin, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML
9:30–11:00 a.m.
Orange County Convention Center Valencia Room W415D
Abstract 487: A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk myelodysplastic syndromes
Speaker: Ian Bouligny, M.D.
Abstract 489: Safety and efficacy results from a Phase Ib study of R289, a dual irak 1/4 inhibitor, in patients with relapsed/refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS)
Speaker: Guillermo Garcia-Manero, M.D.
Abstract 491: A Phase II dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
Speaker: Guillermo Garcia-Manero, M.D.
902. Health Services and Quality Improvement: Lymphoid Malignancies: Redefining supportive care: Development of novel safety, patient engagement, and delivery models in hematologic oncology
9:30–11:00 a.m.
Orange County Convention Center W230
Abstract 517: Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)
Speaker: Vanthana Bharathi
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing Risk Stratification, Treatment and Diagnostics of ALL in the Immunotherapy Era
12:00–1:30 p.m.
Orange County Convention Center W224ABEF
Abstract 549: Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia
Speaker: Roberta Santos Azevedo, M.D.
Abstract 551: A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type and clinical outcomes
Speaker: Manuel Maroun, M.D.
622. Lymphomas: Translational - Non-Genetic: T cell interactions in the lymphoma microenvironment - the good and the bad
12:00-1:30 p.m.
Orange County Convention Center Tangerine Ballroom F1
Abstract 555: Integrative profiling of t-follicular helper cells heterogeneity and tumor microenvironment signatures in angioimmunoblastic T cell lymphoma
Speaker: Tania Sainz
723. Allogeneic Transplantation: Long-Term Follow-Up, Complications and Disease Recurrence: Predicting and Elucidating Relapse
12:00–1:30 p.m.
Orange County Convention Center W331
Abstract 592: Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation
Speaker: Portia Smallbone, M.B.B.S.
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing
12:00–1:30 p.m.
Orange County Convention Center W304ABCD
Moderator: Hugo Lara-Martinez, M.D.
908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real World
12:00–1:30 p.m.
Orange County Convention Center W414CD
Abstract 604: Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis
Speaker: Vaishali Gautam
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and Chemotherapy Combinations in AML
4:30–6:00 p.m.
Orange County Convention Center Chapin Theater (W320)
623. Mantle Cell, Follicular, Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma
4:30–6:00 p.m.
Orange County Convention Center Tangerine Ballroom F2
Abstract 663: Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from a Phase I/II study
Speaker: Michael Wang, M.D.
Abstract 665: Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL): Final update from the Phase I/II BRUIN study
Speaker: Michael Wang, M.D.
Abstract 666: Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk mantle cell lymphoma: The window-3 clinical trial
Speaker: Preetesh Jain, M.B.B.S., M.D., D.M., Ph.D.
628. Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas
4:30–6:00 p.m.
Orange County Convention Center Tangerine Ballroom F3-4
Abstract 670: Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results
Speaker: Jason Westin, M.D.
636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression
4:30–6:00 p.m
Orange County Convention Center Valencia Room W415A
Abstract 674: Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in myelodysplastic syndromes after stem cell transplant
Speaker: Yu-Hsiang Chen, Ph.D.
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL
4:30–6:00 p.m.
Orange County Convention Center W224ABEF
Abstract 681: Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL
Speaker: Mahesh Swaminathan, M.D.
654. Multiple Myeloma: Pharmacologic Therapies: Bi, Tri and Beyond: Innovations in Bispecific and Trispecific Antibodies for Multiple Myeloma
4:30–6:00 p.m.
Orange County Convention Center West Hall E1
Abstract 697: Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial results from the window of opportunity Phase I/II LINKER-MM4 trial
Speaker: Robert Orlowski, M.D., Ph.D.
907. Outcomes Research: Plasma Cell Disorders: Therapeutic Toxicity in Multiple Myeloma: Real-World Evidence and Clinical Approaches
4:30–6:00 p.m.
Orange County Convention Center West Hall D1
Abstract 716: Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR
Speaker: Muhammad Bilal Abid, M.D.
908. Outcomes Research: Myeloid Malignancies: Real-World Experiences
4:30–6:00 p.m.
Orange County Convention Center W414CD
Abstract 725: Real-world treatment patterns and outcomes in patients with myelofibrosis who presented with thrombocytopenia and anemia at initiation of pacritinib treatment
Speaker: Naveen Pemmaraju, M.D.
Scientific Spotlight Session
The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms and Novel Strategies to Overcome It
4:30–5:45 p.m.
Orange County Convention Center Sunburst Room (W340)
Strategies to reduce immune rejection of off-the-shelf cell therapies
Co-Chair and Speaker: May Daher, M.D.
ASH Poster Walk
ASH Poster Walk on Chemotherapy-Free Treatments for Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma Hosted by Blood Neoplasia
8:00–9:00 a.m.
Orange County Convention Center West Halls B3-B4
Chair: Paolo Strati, M.D.
Monday, December 8
Oral Abstract Sessions
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Predicting and Improving Outcomes in Common and Rare Subgroups of Pediatric ALL
10:30 a.m.–12:00 p.m.
Orange County Convention Center W224CDGH
Abstract 759: Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens
Speaker: Sankalp Arora, M.B.B.S.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors and FLT3 Inhibitors in AML
10:30 a.m.–12:00 p.m.
Orange County Convention Center Chapin Theater (W320)
Abstract 763: Monotherapy update from Phase I portion in Phase I/II trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia
Speaker: Naval Daver, M.D.
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma
10:30 a.m.–12:00 p.m.
Orange County Convention Center Tangerine Ballroom F1
Abstract 775: Interim analysis of safety and efficacy in a Phase II study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma
Speaker: Swaminathan Iyer, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Lower-Risk Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
10:30 a.m.–12:00 p.m.
Orange County Convention Center Valencia Room W415A
Abstract 790: Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
Speaker: Guillermo Garcia-Manero, M.D.
702. CAR T Cell Therapies: Basic and Translational: Mechanisms of CAR-T Cell Toxicity and Persistence
10:30 a.m.–12:00 p.m.
Orange County Convention Center W331
Abstract 806: Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients
Speaker: Anath Lionel, M.D., Ph.D.
907. Outcomes Research: Plasma Cell Disorders: Special Populations in Plasma Cell Disorders: Efficacy and Safety of Therapies in Real-World Settings
10:30 a.m.–12:00 p.m.
Orange County Convention Center West Hall E2
Abstract 823: Real-world outcomes of bispecific T cell engagers in plasma cell leukemia
Speaker: Mahmoud Gaballa, M.D.
Abstract 824: Outcomes of bispecific T cell engagers in MM patients with central nervous system (CNS) involvement
Speaker: Mahmoud Gaballa, M.D.
623. Mantle Cell, Follicular, Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination Therapy for MCL
2:45–4:15 p.m.
Orange County Convention Center Tangerine Ballroom F1
Abstract 885: Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the Phase III ECHO trial after 50 months of follow-up
Speaker: Michael Wang, M.D.
626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-World Data on Clinical Predictors of Outcome
2:45–4:15 p.m.
Orange County Convention Center Tangerine Ballroom F3-4
Abstract 895: Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort
Speaker: Chijioke Nze, M.D.
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes
2:45–4:15 p.m.
Orange County Convention Center Chapin Theater (W320)
Abstract 901: CARDINAL: A Phase I study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML
Speaker: Elias Jabbour, M.D.
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-Transplant Cyclophosphamide and Beyond
2:45–4:15 p.m.
Orange County Convention Center W331
Abstract 932: Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies
Speaker: Samer Srour, M.B., Ch.B.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Combination Regimens and Targeted Therapies
4:30–6:00 p.m.
Orange County Convention Center Chapin Theater (W320)
Abstract 977: Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome
Speaker: Roberta Santos Azevedo, M.D.
Wednesday, December 10
ASH Poster Walk
ASH Poster Walk on Population Health and Access to Care
10:00–11:00 a.m.
ASH Virtual Platform
Chair: Warren Fingrut, M.D.
Posters
Saturday, December 6
Poster Abstract Sessions
5:30–7:30 p.m.
Orange County Convention Center West Halls B3–B4
114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I
Abstract 1174: The national burden of opoid use disorder on hospital outcomes in sickle cell disease: A database review and analysis
Presenter: Kaung Htet Hla Win, M.B.
Abstract 1196: The impact of viral pneumonia on hospital outcomes in sickle cell disease: A database review and analysis
Presenter: Kaung Htet Hla Win, M.B.
401. Blood Transfusion: Poster I
Abstract 1368: GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia
Presenter: Hila Shaim, M.D., Ph.D.
Recipient of the 2025 ASH Abstract Achievement Award
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I
Abstract 1435: A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder
Presenter: Leticia Campoverde, M.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Abstract 1496: Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in acute myeloid leukemia
Presenter: Saurabh Kumar Gupta, Ph.D.
Abstract 1497: Preclinical activity of investigational menin inhibitor DSP-5336 (enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models
Presenter: Warren Fiskus, M.D.
Abstract 1500: Identifying novel ‘druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML
Presenter: Christopher Mill, Ph.D.
Abstract 1510: Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged acute myeloid leukemia
Presenter: Yuki Nishida, M.D., Ph.D.
Abstract 1513: Mechanistic approach exploring combination agents to potentiate anti-leukemia activity of Hu8F4, a clinical stage T cell receptor mimic antibody
Presenter: Anna Sergeeva, Ph.D.
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I
Abstract 1558: Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring
Presenter: Trevor Jamison, M.D.
Abstract 1556: Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia
Presenter: Hannah Goulart, M.D.
Abstract 1544: Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens
Presenter: Grace Park, Pharm.D.
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I
Abstract 1566: Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Presenter: Hannah Goulart, M.D.
Abstract 1567: The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a Phase II study
Presenter: Hannah Goulart, M.D.
Abstract 1571: Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a Phase II study
Presenter: Hannah Goulart, M.D.
Abstract 1573: Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial results of a prospective Phase II trial
Presenter: Jayastu Senapati, M.B.B.S., M.D., D.M.
Abstract 1578: Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis
Presenter: Koji Sasaki, M.D., Ph.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Measurable Residual Disease in Diagnosis and Prognosis: Poster I
Abstract 1593: Protein expression signatures reveal age-specific risk patterns in B-ALL
Presenter: Samanta Catueno, M.D.
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
Abstract 1620: Clinical characteristics, demographics and survival outcomes in newly diagnosed CUX1-mutated acute myeloid leukemia
Presenter: Michelle Nwachukwu, D.O.
Abstact 1630: Cladribine, cytarabine and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed acute myeloid leukemia undergoing allogeneic stem cell transplantation
Presenter: Roberta Santos Azevedo, M.D.
Abstract 1634: Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor acute myeloid leukemia
Presenter: Roberta Santos Azevedo, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Abstract 1641: Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies
Presenter: Tapan Kadia, M.D.
Abstract 1642: BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A Phase I dose escalation study
Presenter: Courtney DiNardo, M.D.
Abstract 1646: A Phase I study of the T cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms
Presenter: Tapan Kadia, M.D.
Abstract 1652: A Phase I/II study of GB3226, a novel dual inhibitor of ENL-yeats and FLT3, in patients with relapsed/refractory acute myeloid leukemia
Presenter: Abhishek Maiti, M.B.B.S.
Abstract 1653: Phase Ib study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia
Presenter: Abhishek Maiti, M.B.B.S.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I
Abstract 1678: Cladribine, idarubicin and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated acute myeloid leukemia: A pooled analysis of prospective trials
Presenter: Hannah Goulart, M.D.
Abstract 1688: Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) acute myeloid leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)
Presenter: Farah Al Haj, M.D.
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract 1724: Therapy related core binding factor acute myeloid leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory analysis from a Phase II trial
Presenter: Jayastu Senapati, M.B.B.S., M.D., D.M.
Abstract 1726: Characteristics, genomic landscape and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed acute myeloid leukemia (AML)
Presenter: Roberta Santos Azevedo, M.D.
621. Lymphomas: Translational – Molecular and Genetic: Poster I
Abstract 1764: Artificial intelligence predicts genetic network disruptions to overcome CAR T resistance in mantle cell lymphoma
Presenter: Fangfang Yan, Ph.D.
Abstract 1765: Dissecting pirtobrutinib resistance in mantle cell lymphoma through single-cell multi-omics
Presenter: Fangfang Yan, Ph.D.
622. Lymphomas: Translational - Non-Genetic: Poster I
Abstract 1785: Enhancing the expansion of naïve, potent T cells via BTK inhibition reinvigorates CD19 CAR T cell immunity and boosts antitumor efficacy in relapsed mantle cell lymphoma
Presenter: Yixin Yao
623. Mantle Cell, Follicular, Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Abstract 1829: Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia
Presenter: Anath Lionel, M.D., Ph.D.
Abstract 1837: Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed/refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium
Presenter: Chijioke Nze, M.D.
624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I
Abstract 1844: Autologous CD30 CAR T cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the CHARIOT trial
Presenter: Sairah Ahmed, M.D.
Abstract 1852: Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma
Presenter: Karan Chohan
625. T Cell, NK Cell or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I
Abstract 1869: Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis
Presenter: Chitra Hosing, M.D.
Abstract 1872: Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas
Presenter: Swami Iyer, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster I
Abstract 1931: Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
Presenter: Anath Lionel, M.D., Ph.D.
629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I
Abstract 1967: Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative U.S. bispecific consortium study
Presenter: Kunhwa Kim, M.D.
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I
Abstract 1983: AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)
Presenter: Andrew Dunbar, M.D.
Abstract 3759: EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)
Presenter: Linda Fabris, Ph.D.
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Abstract 2010: Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast phase
Presenter: Mina Abdelmalek, M.D.
Abstract 1539: Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias
Presenter: Mikaela Garza
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Abstract 2037: Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders
Presenter: Hannah Goulart, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I
Abstract 2075: Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes
Presenter: Kelly Chien, M.D.
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
Abstract 2115: Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase I/II BRUIN study with more than 5 years follow-up
Presenter: William Wierda, M.D., Ph.D.
701. Experimental Transplantation: Basic and Translational: Poster I
Abstract 2306: LRP-1 regulates T cell proliferation and activation through global lipid network and loss of LRP-1 eliminates GVHD in vivo
Presenter: Qing Ma, Ph.D.
702. CAR T Cell Therapies: Basic and Translational: Poster I
Abstract 2337: A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies
Presenter: Cuong Le, Ph.D.
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Abstract 2511: Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation
Presenter: Betul Oran, M.D.
Abstract 2515: Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation
Presenter: Betul Oran, M.D.
Abstract 4294: Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center
Presenter: Alexandre Bazinet, M.D.
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I
Abstract 2648: Inclusive practices for safe and equitable donor assessment
Presenter: Warren Fingrut, M.D.
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Abstract 2713: Safety and efficacy of implanted port use for CAR T cells infusion in large B-cell lymphoma
Presenter: Zachary Hunzeker, M.D.
Abstract 2716: Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis
Presenter: Bryan Valcarcel, M.D.
Abstract 2719: Prehabilitation prior to CAR T cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes
Presenter: Rahul Shah, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster I
Abstract 2836: Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database
Presenter: Naveen Pemmaraju, M.D.
Sunday, December 7
Poster Abstract Sessions
Orange County Convention Center West Halls B3–B4
6:00–8:00 p.m.
102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II
Abstract 2906: Safety and efficacy analysis of IV iron formulations in children: Results from a large pediatric cohort
Presenter: Reeja Raj
201. Granulocytes, Monocytes, and Macrophages: Poster II
Abstract 2980: Hodgkin lymphoma-driven hemophagocytic lymphohistiocytosis (HLH) in a predominantly hispanic cohort: A multicenter analysis of clinical features and treatment outcomes
Presenter: Mitchell Boshkos, D.O.
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II
Abstract 3091: National trends in mortality due to disseminated intravascular coagulation and sepsis: A 21-year analysis of hematologic emergencies in the United States
Presenter: Sidra Naz, M.D.
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Abstract 3131: Thrombosis and outcomes in hematologic neoplasia: Experience from a specialized cancer center in a developing country
Presenter: Jhoan Sebastian Gonzalez Diaz, M.D.
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II
Abstract 3160: A multi-site break through cancer pilot study testing the feasibility and safety of therapeutic intervention for patients with high-risk clonal cytopenia of undetermined significance (CCUS)
Presenter: Danielle Hammond, M.D.
508. Bone Marrow Failure: Acquired: Poster II
Abstract 3206: Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia
Presenter: Eitan Kugler, M.D., Ph.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Abstract 3266: Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML
Presenter: Bing Carter, Ph.D.
Abstract 3276: CSF1R-CSF1 axis blockade with axatilimab effectively targets leukemia stem cells and monocytes in AML resistant to BH3 mimetics
Presenter: Bing Carter, Ph.D.
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
Abstract 3314: MYC/GSPT1 protein degradation in refractory/relapsed T-cell prolymphocytic leukemias
Presenter: Yuki Nishida, M.D., Ph.D.
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
Abstract 3326: Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming
Presenter: Bouthaina Dabaja, M.D.
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II
Abstract 3348: Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission
Presenter: Hannah Goulart, M.D.
Abstract 3350: Consolidation with CAR T cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab
Presenter: Hannah Goulart, M.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II
Abstract 3370: Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission
Presenter: David McCall, M.D.
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Abstract 3397: Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy
Presenter: Sankalp Arora, M.B.B.S.
Abstract 3399: ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with acute myeloid leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)
Presenter: Jennifer Marvin-Peek, M.D.
Abstract 3405: Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia
Presenter: Vanthana Bharathi
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
Abstract 3428: Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML
Presenter: Ghayas Issa, M.D.
Abstract 3429: Camelot-2: A Phase III randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy
Presenter: Elias Jabbour, M.D.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II
Abstract 3459: Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax
Presenter: Niranjan Khaire, M.B.B.S., M.D., D.M.
Abstract 3461: Post-transplant maintenance with revumenib in children with HOX-driven AML
Presenter: Branko Cuglievan, M.D.
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II
Abstract 3492: Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status
Presenter: Steven Kornblau, M.D.
Abstract 3503: A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia
Presenter: Sara Nofal, M.D., Ph.D.
621. Lymphomas: Translational – Molecular and Genetic: Poster II
Abstract 3545: The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status
Presenter: Rosalie Griffin, Ph.D.
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Abstract 3571: A Phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma
Presenter: Paolo Strati, M.D.
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II
Abstract 3653: Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia
Presenter: Roberta Santos Azevedo, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster II
Abstract 3717: Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma
Presenter: Sattva Neelapu, M.D.
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Abstract 3758: Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis
Presenter: Wei Xiao, Ph.D.
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Abstract 3795: The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase I/II study final results
Presenter: Prithviraj Bose, M.D.
Abstract 3803: Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis
Presenter: Prithviraj Bose, M.D.
Abstract 3813: Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort
Presenter: Annie Hoai Nguyen
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II
Abstract 3636: Clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study
Presenter: Bryan Valcarcel, M.D.
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II
Abstract 3691: Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma
Presenter: Eduardo Edelman Saul, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster II
Abstract 3709: Targeting B- and T cell lymphomas with anti-CXCR5 CAR T cell therapy
Presenter: Jinsheng Weng, M.D., Ph.D.
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Abstract 8947: Long-term rusfertide treatment in polycythemia vera: Initial results from the Phase II THRIVE extension study
Presenter: Naveen Pemmaraju, M.D.
636. Myelodysplastic Syndromes: Basic and Translational: Poster II
Abstract 3832: Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia
Presenter: Guillermo Montalban-Bravo, M.D.
Abstract 3839: Synergistic apoptotic effect by the combination of clk inhibitor CTX-712 and BCL-2 inhibitor ABT-199 with or without azacytidine in AML and MDS
Presenter: Hui Yang, Ph.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
Abstract 3848: Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition
Presenter: Guillermo Montalban-Bravo, M.D.
Abstract 3849: Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia
Presenter: Guillermo Montalban-Bravo, M.D.
Abstract 3867: Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia
Presenter: Kelly Chien, M.D.
Abstract 3874: A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
Presenter: Guillermo Montalban-Bravo, M.D.
907. Outcomes Research: Plasma Cell Disorders: Poster II
Abstract 4575: Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in relapsed/refractory multiple myeloma
Presenter: Christen Dillard, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster II
Abstract 4613: Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center
Presenter: Mahesh Swaminathan, M.D.
Abstract 4634: Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center
Presenter: Mahesh Swaminathan, M.D.
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Abstract 3892: Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase Ib study
Presenter: Nitin Jain, M.D.
653. Multiple Myeloma: Clinical and Epidemiological: Poster II
Abstract 3987: Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant
Presenter: Oren Pasvolsky, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
Abstract 3857: RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation
Presenter: Roberta Santos Azevedo, M.D.
703. Cellular Immunotherapies other than CAR-T Cells: Poster II
Abstract 4137: Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity
Presenter: Sandeep Singh, Ph.D.
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
Abstract 4148: Intratumoral cellular immunotherapy with autologous hyperactivated M1 SIRPα-low macrophages in non-Hodgkin lymphoma: Clinical results from a first-in-human Phase I study
Presenter: Paolo Strati, M.D.
903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II
Abstract 4435: Incidence burden of AML across the US and Puerto Rico: A two-decade analysis of trends and disparities (1999-2021)
Presenter: Ummul Asfeen, D.O.
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
Abstract 4470: Systematic review and meta-analysis of randomized controlled trials on outpatient thromboprophylaxis (OTP) in patients with cancers with khorana score (KS) ≥ 2 receiving chemotherapy
Presenter: Yin Mon Myat, M.B., B.Ch.
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Abstract 4482: Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis
Presenter: Preetesh Jain, M.B.B.S., M.D., D.M., Ph.D.
908. Outcomes Research: Myeloid Malignancies: Poster II
Abstract 4605: Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm
Presenter: Naveen Pemmaraju, M.D.
Monday, December 8
Poster Abstract Sessions
Orange County Convention Center West Halls B3–B4
6:00–8:00 p.m.
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
Abstract 4909: Risk of venous thromboembolism associated with CDK 4/6 inhibitors and adjuvant hormonal therapy in non-metastatic breast cancer: A systematic review and meta-analysis
Presenter: Elyse Cortez, M.D.
503. Clonal Hematopoiesis, Aging and Inflammation: Poster III
Abstract 4952: The role of Tet2-mutant clonal hematopoiesis in solid tumor immunology
Presenter: Shelley Herbrich, Ph.D.
506. Bone Marrow Microenvironment: Poster III
Abstract 4957: iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs
Presenter: Olayinka Okeleji, M.D.
602. Myeloid Oncogenesis: Basic: Poster III
Abstract 5028: Hnrnpk haploinsufficiency in del(9q) acute myeloid leukemia reveals targetable vulnerabilities
Presenter: Sean Post, Ph.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
Abstract 5050: Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML
Presenter: Kazuharu Kamachi, M.D., Ph.D.
Abstract 5053: Preclinical efficacy of dual BET/HAT inhibitor-based combinations against post myeloproliferative neoplasm secondary AML cells
Presenter: Warren Fiskus, M.D.
Abstract 5055: Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in acute myeloid leukemia
Presenter: Priyanka Sharma, Ph.D.
Abstract 5057: A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in acute myeloid leukemia
Presenter: Liang Zhang, Ph.D.
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
Abstract 5112: Predictors of outcome in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia
Presenter: Vanthana Bharathi
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III
Abstract 5117: Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a Phase I/II dose expansion study with extended follow-up
Presenter: Elias Jabbour, M.D.
Abstract 5131: Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia
Presenter: Hannah Goulart, M.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Measurable Residual Disease in Diagnosis and Prognosis: Poster III
Abstract 5150: Longitudinal clonotype tracking by next-generation sequencing (NGS) based T cell receptor (TCR) rearrangement measurable residual disease (MRD) assay in frontline adult T-acute lymphoblastic leukemia (ALL)
Presenter: Niranjan Khaire, M.B.B.S., M.D., D.M.
Abstract 5151: A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL
Presenter: Eitan Kugler, M.D., Ph.D.
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
Abstract 5156: Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML
Presenter: Reeja Raj, D.O.
Abstract 5167: Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia
Presenter: Sankalp Arora, M.B.B.S.
Abstract 5179: Acute myeloid leukemia with deletion 12p: An adverse-risk disease
Presenter: William Marrero, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
Abstract 5194: A Phase I/II, first-in-human, multicenter, open-label trial evaluating the safety, tolerability and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)
Presenter: Naval Daver, M.D.
Abstract 5195: Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the CADENZA study
Presenter: Naveen Pemmaraju, M.D.
Abstract 5204: Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias
Presenter: Hannah Goulart, M.D.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III
Abstract 9686: A Phase II study of azacitidine, venetoclax and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia
Presenter: Sankalp Arora, M.B.B.S.
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Abstract 5258: High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia
Presenter: Steven Kornblau, M.D.
Abstract 5273: Quantifying treatment-associated monocytic differentiation in AML using a single-cell based myeloid differentiation index (MDX)
Presenter: Li Li, M.D., Ph.D.
623. Mantle Cell, Follicular, Waldenstrom's and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
Abstract 5369: Phase II trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MD Anderson trial
Presenter: Dai Chihara, M.D., Ph.D.
Abstract 5393: Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative U.S. bispecifics consortium study
Presenter: Tony Zhuang, M.D.
Abstract 5422: EPCORE FL-2 Phase III trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress
Presenter: Paolo Strati, M.D.
625. T Cell, NK Cell or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
Abstract 5422: Durable responses in the updated 2-year follow-up of patients from a single-center with relapsed/refractory peripheral T cell lymphoma treated with golidocitinib
Presenter: Eduardo Edelman Saul, M.D.
Abstract 5432: Single center updated analysis of patients with relapsed/refractory peripheral T cell lymphoma treated with linperlisib
Presenter: Ranjit Nair, M.D.
Abstract 5434: A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)
Presenter: Eduardo Edelman Saul, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster III
Abstract 5485: Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CAR T: Planned interim futility analysis of a Phase II trial
Presenter: Mark Hamilton, M.D., Ph.D.
Abstract 5500: Impact of putative cell of origin on CD19+CAR T outcomes in patients with large B-cell lymphoma
Presenter: Muhammad Bilal Abid, M.D.
629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III
Abstract 5525: Trial in progress: Phase II trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma
Presenter: Rahul Shah, M.D.
Abstract 5520: Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma
Presenter: Karan Chohan
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
Abstract 5526: Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study
Presenter: Naveen Pemmaraju, M.D.
Abstract 5542: Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen
Presenter: Ivo Veletic, M.D.
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III
Abstract 5550: Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis
Presenter: Fadi Haddad, M.D.
Abstract 5564: Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor
Presenter: Fadi Haddad, M.D.
Abstract 5565: Asciminib for newly diagnosed chronic myeloid leukemia: Results from a Phase II trial
Presenter: Fadi Haddad, M.D.
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Abstract 5602: Dose intensive regimen of CK0804 tregs in myelofibrosis
Presenter: Lucia Masarova, M.D.
636. Myelodysplastic Syndromes: Basic and Translational: Poster III
Abstract 5613: Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the COMMANDS trial
Presenter: Guillermo Garcia-Manero, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
Abstract 5641: Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes
Presenter: Alex Bataller, M.D., Ph.D.
Abstract 5644: Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling
Presenter: Ziyi Li, Ph.D.
Abstract 5645: Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure
Presenter: Roberta Santos Azevedo. M.D.
Abstract 5647: A Phase I/II trial of azacitidine and venetoclax in previously untreated myelodysplastic syndromes
Presenter: Ian Bouligny, M.D.
Abstract 5648: Luspatercept response predictors in lower-risk myelodysplastic syndrome
Presenter: Vanthana Bharathi
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Abstract 5685: Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia
Presenter: Alexandra Lovell, Pharm.D.
Abstract 5686: Long progression-free survival with venetoclax consolidation in patients with high-risk chronic lymphocytic leukemia treated wit ibrutinib
Presenter: Vishrut Shah, M.D.
Abstract 5687: Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-naïve CLL patients in prospective clinical trials
Presenter: Mahesh Swaminathan, M.D.
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
Abstract 5737: Hyperuricemia modifies multiple myeloma pathobiology and modulates conventional, novel and immuno-oncology drug sensitivity
Presenter: Upasana Ray, Ph.D.
653. Multiple Myeloma: Clinical and Epidemiological: Poster III
Abstract 5769: Extended treatment-free hospitalization-free time and quality of life benefits with CAR T cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial
Presenter: Krina Patel, M.D.
654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Abstract 5834: Final results of a multi-center Phase II trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)
Presenter: Sheeba Thomas, M.D.
703. Cellular Immunotherapies other than CAR-T Cells: Poster III
Abstract 5915: Reactivating mutant p53 in T cells enhances anti-tumor activity in acute myeloid leukemia
Presenter: Li Li, M.D., Ph.D.
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Abstract 5921: Correlative data from an ongoing Phase I, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for acute myeloid leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action
Presenter: Muharrem Muftuoglu, M.D.
Abstract 5938: Long term follow up autologous CD30 CAR T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy
Presenter: Sairah Ahmed, M.D.
Abstract 5951: Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients
Presenter: Mark Forsberg, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III
Abstract 5994: CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide
Presenter: Rima Saliba, Ph.D.
Abstract 5996: MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based GVHD prophylaxis
Presenter: Rima Saliba, Ph.D.
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Abstract 6022: Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A Phase I/II trial
Presenter: Issa Khouri, M.D.
723. Allogeneic Transplantation: Long-term Follow-up, Complications and Disease Recurrence: Poster III
Abstract 6058: Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD Anderson symptom inventory (MDASI-BMT)
Presenter: Portia Smallbone, M.B.B.S.
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
Abstract 6163: Prospective observational cohort study to collect granular social determinants of health data for hematopoietic cell transplant patients
Presenter: Warren Fingrut, M.D.
Abstract 6174: Cost analysis compared with efficacy shows iron dextran surpassing other intravenous iron formulations in children: A tertiary children’s hospital experience
Presenter: Reeja Raj, D.O.
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
Abstract 6299: PET imaging biomarkers predict survival in peripheral T cell lymphoma: A systematic review and meta-analysis
Presenter: Lohitha Dhulipalla, M.D.
Abstract 13008: Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma
Presenter: Rahul Shah, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster III
Abstract 6391: Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database
Presenter: Prithviraj Bose, M.D.
Abstract 6407: Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center
Presenter: Mahesh Swaminathan, M.D.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.